Expanding Access to CAR T-Cell Therapy in Large B-Cell Lymphoma

As the program concludes, Dr. Melody asks Dr. Perales and Dr. Shah to share key takeaways for community oncologists and discuss emerging real-world data and innovations that could improve access to CAR T-cell therapy for patients with large B-cell lymphoma. Dr. Perales emphasizes the potentially curative and transformative role of CAR T-cell therapy and the importance of addressing barriers such as geographic distance and treatment-center capacity. He highlights the value of expanding the geographic footprint of CAR T-cell delivery and strengthening partnerships between cell therapy centers and community oncologists, particularly as patients increasingly return home earlier and require ongoing monitoring for cytopenias, infections, and other late toxicities. Dr. Shah reinforces the importance of early and frequent referral, noting that academic centers can help address logistical, social, and financial barriers. Looking ahead, he describes continued advances toward faster, safer, and more accessible CAR T-cell therapy, including shorter manufacturing timelines and approaches targeting multiple antigens. The discussion closes by emphasizing early referral and coordinated care to broaden appropriate access for patients with large B-cell lymphoma.